Ibex said it will use proceeds from the series B round to support an expanding customer base of clinical deployments in labs and health systems in North America and Europe and grow talent across R&D, clinical and commercial teams. The firm said the investment will also accelerate the expansion of the Galen solution portfolio at Ibex, bringing new AI tools for more tissue types, including novel AI-based enhancements of the pathology workflow and oncology-focused AI-markers. Ibex is at the forefront of digital transformation in pathology and we are committed to supporting our customers on their AI journey, said Joseph Mossel, Ibex CEO and Co-founder. Quality diagnosis is our top priority and a cornerstone of cancer care programs. I am proud of our team, demonstrating through clinical studies and, more importantly, in live clinical settings, that our AI is a game-changer in eliminating misdiagnosis and ensuring real-time patient safety. This investment will help us meet t
Results for
Ibex Medical Analytics scores $38M to power cancer diagnostics with AI
The Israeli medtech startup fuels its North American expansion. Ibex CEO: We view AI as the next great wave of transformation in healthcare . Dor Schwartz / 9 Mar 2021 • 3 min read
The ongoing global pandemic has pushed healthcare services to the limit. From crowded hospitals to long diagnosis wait times, COVID has exposed many areas where healthcare may need a virtual hand, even in a post-COVID reality. One area where pathologists have previously struggled is in cancer diagnostics. It could be the lack of skilled personnel, backed up labs, or plain and simple, a rise in cases, but these workload issues can cause critical mishaps during the critical diagnosis process.
AI cancer diagnostics co Ibex Medical Analytics raises $38m globes.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globes.co.il Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
Digital and computational pathology professional, Richard Nicholson, is appointed as Sales Director for the UK and Ireland
TEL AVIV, Israel, Feb. 23, 2021 /PRNewswire/
Ibex Medical Analytics, the pioneer in artificial intelligence (AI)-based cancer diagnostics, today announced the appointment of Richard Nicholson, a seasoned professional of healthcare informatics and digital pathology, as its Sales Director for the UK and Ireland.
With over 15 years of experience in healthcare IT & medical imaging, Richard brings a unique combination of broad market expertise coupled with deep domain knowledge in digital pathology. In his previous role at Google, Richard drove the adoption and digital transformation of NHS organizations with services of Google Cloud. Prior to Google, Richard was Sales Director at Philips UK, where he led its UK and Ireland digital pathology business for over four years. Based out of Newcastle, Richard will lead Ibex s com
Ibex Medical Analytics, a pioneer in artificial intelligence (AI)-based cancer diagnostics, and
KSM, the Research and Innovation Center of Maccabi Healthcare Services – Israel s leading HMO - announced today a first-of-a-kind pilot of Ibex s Galen Breast solution for AI-powered primary diagnosis of breast cancer at Maccabi s Pathology Institute.
Breast cancer is the most common malignant disease in women worldwide, with over 2 million new cases each year. Early and accurate detection is critical for effective treatment and saving women s lives.
Maccabi KSM Logo
The pilot at Maccabi s Pathology Institute includes 2,000 breast biopsies on which pathologists will use Galen Breast as a First Read application. It is the first-ever deployment of an AI application for primary diagnosis of breast cancer.